Regulus Therapeutics, a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, said this week that the US Patent and Trademark Office has allowed claims in a patent application covering microRNA-21.

According to the company, the miRNA is linked to a variety of diseases including cancer, fibrosis, and heart disease. The application, from the so-called Tuschl-III patent series, also covers single-stranded and double-stranded antisense compounds complementary to miR-21, Regulus said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.